Artivion (NYSE:AORT) SVP Marshall Stanton Sells 2,149 Shares

Artivion, Inc. (NYSE:AORT) SVP Marshall Stanton sold 2,149 shares of the company’s stock in a transaction dated Tuesday, March 3rd. The shares were sold at an average price of $37.78, for a total transaction of $81,189.22. Following the transaction, the senior vice president directly owned 60,097 shares of the company’s stock, valued at $2,270,464.66. This represents a 3.45% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Artivion Stock Performance

Shares of AORT stock traded down $0.36 during mid-day trading on Thursday, reaching $38.14. The stock had a trading volume of 112,246 shares, compared to its average volume of 411,444. The firm’s 50 day simple moving average is $41.42 and its 200 day simple moving average is $42.92. The company has a quick ratio of 2.62, a current ratio of 3.53 and a debt-to-equity ratio of 0.49. The firm has a market cap of $1.83 billion, a PE ratio of 190.71 and a beta of 1.60. Artivion, Inc. has a one year low of $21.97 and a one year high of $48.25.

Artivion (NYSE:AORT) last announced its quarterly earnings results on Thursday, February 12th. The company reported $0.17 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.14 by $0.03. Artivion had a net margin of 2.21% and a return on equity of 7.43%. The firm had revenue of $118.30 million for the quarter, compared to analyst estimates of $116.42 million. The business’s revenue for the quarter was up 19.2% compared to the same quarter last year. On average, analysts forecast that Artivion, Inc. will post 0.37 EPS for the current year.

Wall Street Analyst Weigh In

AORT has been the topic of a number of analyst reports. Wall Street Zen cut Artivion from a “buy” rating to a “hold” rating in a research report on Saturday, February 14th. Oppenheimer reaffirmed an “outperform” rating and issued a $50.00 target price on shares of Artivion in a report on Friday, November 7th. Weiss Ratings upgraded shares of Artivion from a “sell (d)” rating to a “hold (c-)” rating in a research report on Friday, February 20th. Stifel Nicolaus set a $55.00 price target on shares of Artivion in a research report on Thursday. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $58.00 price objective on shares of Artivion in a research note on Monday, February 2nd. Six investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to MarketBeat.com, Artivion presently has a consensus rating of “Moderate Buy” and a consensus target price of $50.47.

Hedge Funds Weigh In On Artivion

Large investors have recently modified their holdings of the stock. Royal Bank of Canada increased its holdings in shares of Artivion by 107.0% in the first quarter. Royal Bank of Canada now owns 38,707 shares of the company’s stock valued at $952,000 after purchasing an additional 20,010 shares in the last quarter. AQR Capital Management LLC lifted its stake in shares of Artivion by 8.8% during the first quarter. AQR Capital Management LLC now owns 35,053 shares of the company’s stock valued at $862,000 after acquiring an additional 2,823 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in shares of Artivion by 4.6% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 23,591 shares of the company’s stock valued at $580,000 after acquiring an additional 1,032 shares during the period. Envestnet Asset Management Inc. boosted its holdings in Artivion by 364.4% in the second quarter. Envestnet Asset Management Inc. now owns 52,871 shares of the company’s stock valued at $1,644,000 after acquiring an additional 41,487 shares during the last quarter. Finally, Atria Investments Inc acquired a new stake in Artivion in the second quarter worth about $244,000. 86.37% of the stock is currently owned by institutional investors and hedge funds.

Key Headlines Impacting Artivion

Here are the key news stories impacting Artivion this week:

• Positive Sentiment: Management will present virtually at the Oppenheimer Healthcare MedTech & Services Conference — a near?term event where management can update guidance, commercialization progress or product milestones that could re?ignite buy?side interest. Artivion to Participate in Oppenheimer Conference
• Positive Sentiment: Recent quarterly results beat estimates (EPS and revenue) with ~19% YoY revenue growth — this underpins the growth story and supports analyst conviction. MarketBeat – Artivion Earnings Summary
• Positive Sentiment: Large institutional buying (notably Invesco’s sizable Q4 add and other funds increasing exposure) can provide steadier bid support and signals professional investor confidence. MarketBeat – Institutional Activity
• Neutral Sentiment: Analyst coverage remains constructive (consensus “Moderate Buy” with an average target ? $49) — supportive but much of this view may already be reflected in the stock. MarketBeat – Analyst Ratings
• Neutral Sentiment: Industry/media pieces highlight portfolio expansion and relative EPS performance on the NYSE Composite; useful for narrative but not an immediate market catalyst by itself. Kalkine – Portfolio Expansion Article
• Negative Sentiment: A concentrated wave of insider sales occurred March 2–4 (CEO James Mackin sold tens of thousands of shares across filings, plus multiple EVP/SVP/CAO sales). Markets often interpret clustered senior?level selling as a near?term negative catalyst even though insiders retain large stakes and sales can be for liquidity/tax planning. Monitor for additional filings or company commentary. Insider Trades Alert

About Artivion

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.